Navigation Links
Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
Date:2/25/2009

NEW YORK, Feb. 26, 2009 /PRNewswire-FirstCall/ --Forest Laboratories, Inc. (NYSE: FRX) today announced that a complaint filed against the Company by the United States was unsealed in Massachusetts federal court alleging violations of the federal False Claims Act arising from Forest's marketing of its antidepressants Lexapro(R) and Celexa(R). The Complaint alleges that Forest personnel improperly promoted Lexapro and Celexa for off-label pediatric use, and that Forest paid kickbacks to physicians to induce them to prescribe these drugs. The Company understands that eleven states and the District of Columbia have also filed notices of intention to intervene as plaintiffs in the action. The Company had previously disclosed the government investigation in all periodic reports filed with the SEC since 2004. In its Form 10-Q filing for the period ending September 30, 2008, Forest disclosed the government's intention to assert civil claims against Forest under the False Claims Act. Forest is committed to adhering to the highest ethical and legal standards, and off-label promotion and improper payments to medical providers have consistently been against Forest policy. Forest is currently reviewing the complaint and will respond to this action at the appropriate time. In addition, as previously disclosed, Forest is continuing its discussions with the government about the investigation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
2. Old-Growth Forests Dying Off in U.S. West
3. Forest Laboratories, Inc. Reports Q309 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees
4. Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia
5. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings
6. Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares
7. Forest Laboratories Responds To Unsolicited Mini-Tender Offer
8. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
9. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
10. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
11. Lake Forest, CA: SpeechPhone Launches Handsfree Driving Solution Just in Time to Comply with New Handsfree Driving Laws
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a ... its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, ... power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and ...
(Date:4/28/2017)... Tenn. (PRWEB) , ... April 28, 2017 , ... ... system, today announced an alliance with B. Braun Medical Inc. , a leader ... role in patient care with as many as 90 percent of hospital patients receiving ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... natural deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve used the same ... that actually works! , Countless deodorants flood the aisles that contain harmful chemicals ...
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs announced ... Lincoln, Neb. area this year. , The first new location will open at ... will open at 84th and Northern Lights Drive this fall. And the third location ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology: